Goldman Sachs released a report stating that, according to Wind data, UNITED LAB (03933.HK) maintains favorable pricing for penicillin G and 6-APA, staying at historic highs, although there were some slight price fluctuations for 6-APA in November. The firm expects that the company's pricing trend will remain resilient in the coming quarters, as the expansion speed of a major Indian pharmaceutical company's production capacity is slower than expected.

Goldman Sachs stated that due to a more positive expectation for the company's pricing trend next year, sales and earnings forecasts for 2025 and 2026 have been raised by 8.1%/4.7% and 17.4%/10% respectively. The Target Price has been increased from 9.31 to 10.25.